This inventor holds 4 USPTO granted patents and 11 published patent applications and 2 EPO patents. Top assignees: Regeneron Pharmaceuticals, Inc., University System of Maryland. Active years: 2025-2026.
Company Filing History:
3 out of 1,471 
2 out of 2,020 
Years Active: 2025-2026
Title: Alan Shuldiner: Innovator in Bone Health
Introduction
Alan Shuldiner is a notable inventor based in Tarrytown, NY (US). He has made significant contributions to the field of bone health through his innovative research and patents. His work focuses on addressing decreased bone mineral density, a condition that affects many individuals.
Latest Patents
Alan Shuldiner holds a patent for the treatment of decreased bone mineral density with zinc and ring finger 3 (ZNRF3) inhibitors. This patent outlines methods for treating patients with decreased bone mineral density, identifying subjects at risk, and detecting human Zinc And Ring Finger 3 (ZNRF3) variant nucleic acid molecules and polypeptides. His innovative approach aims to improve the health and quality of life for those affected by this condition.
Career Highlights
Throughout his career, Alan has worked with prominent organizations, including Regeneron Pharmaceuticals, Inc. and the University System of Maryland. His experience in these institutions has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.
Collaborations
Alan has collaborated with various professionals, including his coworker Nehal Gosalia. These partnerships have enhanced his research and led to advancements in the understanding of bone health.
Conclusion
Alan Shuldiner's contributions to the field of bone health through his patent and collaborations highlight his dedication to improving patient outcomes. His innovative work continues to pave the way for future advancements in treating decreased bone mineral density.